CTP-499
| Code | Size | Price |
|---|
| TAR-T31109-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
CTP499, a selective PDE inhibitor, and the deuterium-containing agent is an HDX analogue and a metabolite of hexantheobromine that slows the progression of type 2 diabetic nephropathy in patients with macroalbuminuria.
CAS:
1268605-91-9
Formula:
C13H20N4O3
Molecular Weight:
285.359
Purity:
0.98
SMILES:
[2H]C([2H])([2H])[C@H](O)C([2H])([2H])CCCn1c(=O)n(C)c2ncn(C)c2c1=O
References
1. Perez-Gomez MV, Sanchez-Ni?o MD, Sanz AB, Mart?n-Cleary C, Ruiz-Ortega M, Egido J, Navarro-Gonz?lez JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review. PubMed PMID: 26239562; PubMed Central PMCID: PMC4485003.
2. Tang X, Bridson G, Ke J, Wu L, Erol H, Graham P, Lin CH, Braman V, Zhao H, Liu JF, Lin ZJ, Cheng C. Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:1-9. doi: 10.1016/j.jchromb.2014.05.043. Epub 2014 May 28. PubMed PMID: 24927417.
3. Braman V, Graham P, Cheng C, Turnquist D, Harnett M, Sabounjian L, Shipley J. A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. Clin Pharmacol Drug Dev. 2013 Jan;2(1):53-66. doi: 10.1002/cpdd.3. Epub 2013 Feb 21. PubMed PMID: 27121560.